SARcode Announces Results Of Phase 1 Trial Of SAR 1118 Ophthalmic Solution In Healthy Adult Subjects
SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers. SAR 1118 was well-tolerated and demonstrated a favorable safety profile when administered by topical ocular instillation up to three times daily at dose strengths of up to 5%.
More: continued here
Filed under: Eye Health on April 1st, 2009
You must be logged in to post a comment.